TICKERNERD
Menu
ENGNENGNHealthcare · Biotechnology

ENGN Stock Forecast: enGene Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.79
+1.13% on the day

The 10 Wall Street analysts covering enGene Therapeutics, Inc. hold a median 12-month price target of $4 — +123.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$119.2M
Ticker Nerd rank
27 / 100
Median analyst target
$4.00
Analysts covering
10
Total return, dividends reinvested
1W
+5.3%
1M
−7.3%
YTD
−80.2%
1Y
−54.2%
From 52W high
−85.3%
From 52W low
+24.3%
$1
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ENGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores enGene Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
75
Size
74
Volatility
60
Quality
51
Accruals
49
Growth
31
Issuance
13
Momentum
12
Value
8

Revisions (75): Analysts have, on balance, been raising their forecasts.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ENGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$2$4$6$8$10$12Oct 25Jan 26Apr 26Jul 26ENGNHigh $5.00Median $4.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
3 Buy6 Hold1 Sell
Low $2.00Median $4.00High $5.00

The green dot is the last close — the median target sits +123.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 June 2026Morgan StanleyDowngradeUnderweight—
18 June 2026Morgan StanleyDowngradeUnderweight—
16 June 2026HC Wainwright & Co.MaintainsBuy$6.00 → $4.00
16 June 2026HC Wainwright & Co.MaintainsBuy—
14 May 2026UBSMaintainsNeutral—
8 May 2026CitizensDowngradeMarket Perform—
8 May 2026GuggenheimDowngradeNeutral—
8 May 2026HC Wainwright & Co.MaintainsBuy—
8 May 2026Piper SandlerDowngradeNeutral—
8 May 2026Wells FargoDowngradeEqual-Weight—
13 Apr 2026WBB SecuritiesInitiatesBuy—
11 Mar 2026OppenheimerMaintainsOutperform—
9 Mar 2026HC Wainwright & Co.ReiteratesBuy—
12 Nov 2025CitizensMaintainsMarket Outperform—
12 Nov 2025Morgan StanleyMaintainsOverweight—
12 Nov 2025OppenheimerReiteratesOutperform—
12 Nov 2025UBSMaintainsNeutral—
12 Sept 2025HC Wainwright & Co.ReiteratesBuy—
12 Sept 2025Morgan StanleyMaintainsOverweight—
8 Sept 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ENGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
9
Analysts cutting
0
Fundamentals

enGene Therapeutics, Inc. (ENGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 81% of US stocks

Price / sales
—
Price / book
0.5×

Cheaper than 86% of US stocks

EV / EBITDA
0.8×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−52.6%

Higher than 21% of US stocks

Return on assets
−28.9%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ENGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ENGNenGene Therapeutics, Inc.$119.2M
27
COYACoya Therapeutics, Inc.$114.2M
56
SEERSeer, Inc. (California)$114.2M
71
NTHINeOnc Technologies Holdings, Inc.$116.5M
20
RANIRani Therapeutics Holdings, Inc.$120.0M
64
NAUTNautilus Biotechnology, Inc.$121.3M
55
HURATuHURA Biosciences, Inc.$121.4M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own enGene Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENGN news & analysis

enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market

MarketBeat · 13 Aug 2026positive

enGene outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer (NMIBC) market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystectomy, with an eye toward 2027 approval for detalimogene.

Why it matters — An ENGN watcher would care because the company is presenting a market opportunity for detalimogene that could underpin its development timeline toward a 2027 approval.

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript

Seeking Alpha · 11 Aug 2026neutral

enGene Therapeutics participated in a Seeking Alpha transcript discussion covering market insights and clinical development for non-muscle invasive bladder cancer. The item details the company's commentary on this area.

Why it matters — An ENGN watcher would care because the discussion directly addresses the company's clinical development strategy and market positioning in its key non-muscle invasive bladder cancer program.

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

Business Wire · 4 Aug 2026neutral

enGene Therapeutics announced it will host a virtual key opinion leader event on August 11, 2026 at 11:00 AM ET, featuring urologist Dr. Neal Shore, who will join management to discuss the evolving non-muscle invasive bladder cancer (NMIBC) treatment landscape and related considerations.

Why it matters — The event offers enGene watchers insight into the NMIBC market landscape, which is relevant to enGene's clinical-stage, non-viral genetic medicines work in that area.

FAQ

Frequently asked questions about ENGN stock

What is the ENGN stock price forecast for 2026-2027?

The 10 Wall Street analysts covering enGene Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ENGN stock a buy right now?

Of the 10 analysts covering enGene Therapeutics, Inc., 3 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks enGene Therapeutics, Inc. 27 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENGN?

As at 22 Aug 2026, enGene Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (75 of 100).

Will ENGN stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +123.5% from the last close, and Ticker Nerd's factor model ranks enGene Therapeutics, Inc. 27 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ENGN stock forecast for 2030?

No analyst covering enGene Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.

How has ENGN stock performed over the past year?

enGene Therapeutics, Inc. returned -54.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does enGene Therapeutics, Inc. do?

enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on mainstreaming gene therapy through non-viral delivery of therapeutics to mucosal tissues and other organs.

What is the latest news on ENGN?

The most recent item we track (MarketBeat, 13 Aug 2026): "enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market". enGene outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer (NMIBC) market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystectomy, with an eye toward 2027 approval for detalimogene.

Company

About enGene Therapeutics, Inc.

enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on mainstreaming gene therapy through non-viral delivery of therapeutics to mucosal tissues and other organs. Its lead program, detalimogene voraplasmid (detalimogene), targets non-muscle invasive bladder cancer (NMIBC), particularly in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS), with or without papillary disease. This therapy is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, including a pivotal cohort. enGene Therapeutics Inc. leverages its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables localized delivery of diverse gene cargos such as DNA and various forms of RNA directly to target tissues. Operating in the biotechnology and medical research sector, the company addresses diseases with high unmet clinical needs by developing genetic medicines that penetrate mucosal barriers effectively. Headquartered in Saint-Laurent, Quebec, Canada, enGene Therapeutics Inc. plays a role in advancing innovative treatments for oncology and other challenging indications through its DDX technology.

CEO Mr. Ronald H. W. Cooper · 81 employees · Canada · https://www.engene.com